Definition of “Microvascular Angina” & how to distinguish between angina from #CMD & #CAD
👇
I personally avoid using this term because even when we establish Dx of #CMD, many pts have concomitant epicardial dz &/or Endo Dysfxn; so angina might be multifactorial or 2/2 other 2
✅ @escardio recommend Rx for #CMD:
BBlockers
ACEi
Statins
✅ Our practice (in order):
BBlockers
Statins
ASA (if any CAD)
Nitrates
CCB
Ranolazine
ACEi
(no strong evidence for any of these meds)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#CMD shares similar RFs w epicardial atherosclerosis (traditional ASCVD RFs) & is associated with several biomarkers of inflammation, oxidative stress & coagulation
In our IVUS study:
✅ Most patients with #CMD had significant plaque burden
✅ Patients with #CMD had higher plaque burden & more diffuse atherosclerosis as compared to patients w/o CMD
✅ Angina ➡ poor prognosis
✅ Angina with no obstructive CAD = ⬆ risks of CV events compared to no angina, even after adjusting for traditional RFs & co-morbidities
✅ What Is #CMD & Why Is It Important?
✅ Dx & Risk Stratification of #CMD: Stress Testing & Noninvasive Imaging
✅ Catheter-Based Techniques in Dx of #CMD
✅ Emerging Link Between #CMD & #HFpEF
✅ Phenotype-Based Mngmt of #CMD
🔘 Strengths/Limits of Lesion Specific vs Myocardial Ischemia
🔘 Comparing Dx Accuracy of Tests
🔘 Ischemia Testing in #INOCA
🔘 How to Select Best Noninvasive Test
☢ Issues with proposed #FFR threshold 0.8
☢ Exercise MPI correlates well with FFR but not at 0.8
☢ Benefit of FFR-guided revasc dominantly occurs w/ thresholds <0.8
☢ Quantification of lesion-specific #ischemia insufficient for patient mgmt